Historical Valuation
10X Genomics Inc (TXG) is now in the Fair zone, suggesting that its current forward PS ratio of 2.27 is considered Fairly compared with the five-year average of -101.81. The fair price of 10X Genomics Inc (TXG) is between 17.73 to 187.67 according to relative valuation methord.
Relative Value
Fair Zone
17.73-187.67
Current Price：20.46
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
10X Genomics Inc (TXG) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 5.09 , the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of 9.90, the current P/B ratio is about -100.00% higher. 10X Genomics Inc (TXG) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.15%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -1.63% , the current FCF yield is about -100.00% lower.
P/B
Median3y
5.09
Median5y
9.90
FCF Yield
Median3y
-1.15
Median5y
-1.63
Competitors Valuation Multiple
AI Analysis for TXG
The average P/S ratio for TXG competitors is 3.64, providing a benchmark for relative valuation. 10X Genomics Inc Corp (TXG.O) exhibits a P/S ratio of 2.27, which is -37.58% above the industry average. Given its robust revenue growth of 9.84%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for TXG
1Y
3Y
5Y
Market capitalization of TXG increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TXG in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TXG currently overvalued or undervalued?
10X Genomics Inc (TXG) is now in the Fair zone, suggesting that its current forward PS ratio of 2.27 is considered Fairly compared with the five-year average of -101.81. The fair price of 10X Genomics Inc (TXG) is between 17.73 to 187.67 according to relative valuation methord.
What is 10X Genomics Inc (TXG) fair value?
TXG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of 10X Genomics Inc (TXG) is between 17.73 to 187.67 according to relative valuation methord.
How does TXG's valuation metrics compare to the industry average?
The average P/S ratio for TXG's competitors is 3.64, providing a benchmark for relative valuation. 10X Genomics Inc Corp (TXG) exhibits a P/S ratio of 2.27, which is -37.58% above the industry average. Given its robust revenue growth of 9.84%, this premium appears unsustainable.
What is the current P/B ratio for 10X Genomics Inc (TXG) as of Jan 10 2026?
As of Jan 10 2026, 10X Genomics Inc (TXG) has a P/B ratio of 0.00. This indicates that the market values TXG at 0.00 times its book value.
What is the current FCF Yield for 10X Genomics Inc (TXG) as of Jan 10 2026?
As of Jan 10 2026, 10X Genomics Inc (TXG) has a FCF Yield of 0.00%. This means that for every dollar of 10X Genomics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for 10X Genomics Inc (TXG) as of Jan 10 2026?
As of Jan 10 2026, 10X Genomics Inc (TXG) has a Forward P/E ratio of -9.54. This means the market is willing to pay $-9.54 for every dollar of 10X Genomics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for 10X Genomics Inc (TXG) as of Jan 10 2026?
As of Jan 10 2026, 10X Genomics Inc (TXG) has a Forward P/S ratio of 2.27. This means the market is valuing TXG at $2.27 for every dollar of expected revenue over the next 12 months.